Zim Laboratories Q1 FY27 Earnings Presentation: Revenue Up 31.2% YoY to ₹94.2 Crore
Zim Laboratories reported Q1 FY27 Total Operating Income of ₹94.2 crore, up 31.2% YoY but down 10.5% QoQ. EBITDA decreased 40% YoY to ₹3.4 crore, with margins at 3.7%. PAT was a loss of ₹4 crore. Innovative product revenue grew threefold to ₹13.8 crore, contributing 15% to TOI.
The YoY revenue growth is positive, but the decline in profitability and the sequential drop in revenue indicate some headwinds. The ongoing investments and remediation efforts suggest a focus on long-term strategic development, which may have a moderate impact on investor sentiment.
While revenue showed strong YoY growth, the decline in EBITDA and PAT on a YoY and QoQ basis, along with increased costs, tempers the positive outlook. The company is investing in R&D and remediation, which impacts short-term profitability but aims for future growth.
Zim Laboratories Limited has released its Q1 FY27 earnings presentation, highlighting a significant year-on-year increase in Total Operating Income (TOI) by 31.2% to ₹94.2 crore (₹942 Mn) from ₹71.8 crore (₹718 Mn) in Q1 FY26. However, TOI saw a sequential decline of 10.5% QoQ, attributed to the war situation in the Middle East and logistic challenges, with early signs of improvement noted.
The company's EBITDA for Q1 FY27 stood at ₹3.4 crore (₹34 Mn), a decrease of 40% YoY, with EBITDA margins at 3.7% compared to 7.9% in Q1 FY26. This reduction in margins is primarily due to increased utility and employee costs. The Profit After Tax (PAT) was a loss of ₹4 crore (₹40 Mn), compared to a loss of ₹1.9 crore (₹19 Mn) in Q1 FY26, largely due to the flow-through of lower EBITDA. The increase in depreciation and finance costs is a result of investments made to support future scaling.
The Pharma business contributed 72% (₹67.3 crore) to the total revenue, while the Nutra business contributed 28% (₹26.8 crore). Notably, the Pharma business saw a 20% increase YoY, and the Nutra business grew by 71% YoY. Innovative Product revenue (NIP + OTF) surged threefold YoY to ₹13.8 crore, increasing its contribution to 15% of TOI from 6% in Q1 FY26. Including dossier licensing fees, the innovative product contribution rose to 18% of TOI.
The export business accounted for 84% of the revenue in Q1 FY27, showing a YoY growth of 31.7%, while the domestic business grew by 24% YoY. The company also provided an update on its EU-GMP CAPA remediation, with most of the plan completed and implemented. The company underwent TGA and PIC/S Malaysia audits in addition to the ongoing remediation efforts.
Zim Laboratories has 12 NIP products in active development across 7 therapy areas in the EU/UK, with 3 regulatory approvals secured. They also have 5 OTF products across 3 therapy areas, with 3 regulatory approvals secured. R&D investment has been sustained at over 8% of operating income, with a total R&D allocation of ₹8.2 crore (₹82 Mn) in Q1 FY27 for product development, dossier upgrades, registrations, and infrastructure.
What to do with a filing like this
Zim Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zim Laboratories Limited. Read the original for the full detail.